Publication Name	World Journal of Gastroenterology
Manuscript ID	9337
Country	China

Received	2014-02-09 14:51
Peer-Review Started	2014-02-10 12:11
First Decision by Editorial Office Director
Return for Revision	2014-03-13 10:25
Revised	2014-03-26 10:20
Publication Fee Transferred
Second Decision by Editor	2014-05-14 09:26
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-05-14 09:28
Articles in Press	2014-05-23 10:42
Edit the Manuscript by Language Editor	2014-05-20 22:42
Typeset the Manuscript	2014-08-21 10:10
Publish the Manuscript Online	2014-09-18 19:50

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Case Report
Article Title	Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Cai-Xia Dong, Jian-Fei Fu, Xian-Yun Ye, Xiao-Fen Li, Xian Zhong and Ying Yuan
Funding Agency and Grant Number
Corresponding Author	Ying Yuan, MD, Department of Medical Oncology, 2nd Hospital of Zhejiang University College of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. yuanying1999@zju.edu.cn
Key Words	Gastric adenocarcinoma; Trastuzumab; Oxaliplatin; Capecitabine; Neoadjuvant medication
Core Tip	Surgical resection of advanced gastric cancer is accompanied by a high frequency of recurrences and metastases. To curb cancerous cell growth, cytostatic medications are commonly used; however, tumor cell-specific drugs are being researched increasingly. Human epidermal growth factor receptor 2 (HER2) has been recognized as a target for breast cancer medications, and the application of the monoclonal antibody trastuzumab led to remissions of HER2-positive breast cancers, which comprise about 30% of all cases. HER2 overexpression was also detected in gastric cancers; therefore, trastuzumab as an adjuvant or neoadjuvant therapy has been used as a new approach to treat these tumors.
Publish Date	2014-09-18 19:50
Citation	Dong CX, Fu JF, Ye XY, Li XF, Zhong X, Yuan Y. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol 2014; 20(34): 12355-12358
URL	http://www.wjgnet.com/1007-9327/full/v20/i34/12355.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i34.12355

Full Article (PDF)	WJG-20-12355.pdf
Full Article (Word)	WJG-20-12355.doc
Manuscript File	9337-Review.docx
Answering Reviewers	9337-Answering reviewers.pdf
Copyright License Agreement	9337-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	9337-Language certificate.pdf
Peer-review Report	9337-Peer reviews.pdf
Scientific Editor Work List	9337-Scientific editor work list.pdf